Amir Goldkorn • USC Profiles (original) (raw)

  1. A festschrift in honor of Ian M. Thompson Jr., MD. Urol Oncol. 2025 Jul; 43(7):423-435. Svatek RS, Ankerst DP, D' Amico AV, Flaig TW, Ford LG, Goldkorn A, Hernandez J, Kumar AP, Leach RJ, Lerner S, Liss MA, McConkey DJ, Minasian L, Morilak D, Mueller EJ, Parekh DJ, Platz EA, Sudarshan S, Unger JM. PMID: 40447392.
    View in: PubMed Mentions: Fields:
  2. Combined Transcriptomic and Epitranscriptomic Profiling Identifies THBS1 as A Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Heterog Plast. 2025; 2(2). Hodara E, Swartz L, Mades A, Bsteh D, Xu T, Rhie SK, Goldkorn A. PMID: 40303463; PMCID: PMC12040338.
    View in: PubMed Mentions:
  3. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 10 01; 7(10):e2437871. Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Dorff TB, Lerner SP, Thompson I, Agarwal N. PMID: 39374015; PMCID: PMC11581504.
    View in: PubMed Mentions: 11 Fields:
    Translation:HumansCellsCTClinical Trials
  4. Artificial Intelligence and Radiomics Applied to Prostate Cancer Bone Metastasis Imaging: A Review. iRadiology. 2024 Dec; 2(6):527-538. Pawan SJ, Rich J, Le J, Yi E, Triche T, Goldkorn A, Duddalwar V. PMID: 40453356; PMCID: PMC12124838.
    View in: PubMed Mentions: 1
  5. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300. Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. PMID: 39003201; PMCID: PMC11416320.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  6. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer Prostatic Dis. 2024 Sep; 27(3):566-570. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. PMID: 38424319; PMCID: PMC12036820.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCTClinical Trials
  7. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449. Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM. PMID: 37966367; PMCID: PMC10824507.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCTClinical Trials
  8. m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer. NAR Cancer. 2023 Dec; 5(4):zcad054. Hodara E, Mades A, Swartz L, Iqbal M, Xu T, Bsteh D, Farnham PJ, Rhie SK, Goldkorn A. PMID: 38023731; PMCID: PMC10653028.
    View in: PubMed Mentions: 7 Fields:
  9. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347. Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Lerner SP. PMID: 37414705; PMCID: PMC10659139.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCTClinical Trials
  10. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023 10; 6(5):516-524. Lu YT, Plets M, Morrison G, Cunha AT, Cen SY, Rhie SK, Siegmund KD, Daneshmand S, Quinn DI, Meeks JJ, Lerner SP, Petrylak DP, McConkey D, Flaig TW, Thompson IM, Goldkorn A. PMID: 37087309; PMCID: PMC10587361.
    View in: PubMed Mentions: 16 Fields:
    Translation:HumansCellsCTClinical Trials
  11. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. Eur Urol. 2024 Feb; 85(2):171-176. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N. PMID: 37085425; PMCID: PMC10662935.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansCTClinical Trials
  12. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 06 20; 41(18):3352-3362. Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. PMID: 36996380; PMCID: PMC10414728.
    View in: PubMed Mentions: 29 Fields:
    Translation:HumansCTClinical Trials
  13. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. Mol Cancer Ther. 2022 12 02; 21(12):1857-1861. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. PMID: 36198026.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansCellsCTClinical Trials
  14. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Curr Oncol Rep. 2022 10; 24(10):1287-1298. Tulpule V, Morrison GJ, Falcone M, Quinn DI, Goldkorn A. PMID: 35575959; PMCID: PMC9474724.
    View in: PubMed Mentions: 9 Fields:
    Translation:HumansCells
  15. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 10 01; 40(28):3301-3309. Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM, Quinn DI. PMID: 35446628; PMCID: PMC9553390.
    View in: PubMed Mentions: 22 Fields:
    Translation:HumansCTClinical Trials
  16. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Sci Rep. 2022 04 01; 12(1):5518. Xu T, Junge JA, Delfarah A, Lu YT, Arnesano C, Iqbal M, Delijani K, Hsieh TC, Hodara E, Mehta HH, Cohen P, Graham NA, Fraser SE, Goldkorn A. PMID: 35365706; PMCID: PMC8976067.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  17. FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. Cancers (Basel). 2022 Mar 28; 14(7). Lu YT, Xu T, Iqbal M, Hsieh TC, Luo Z, Liang G, Farnham PJ, Rhie SK, Goldkorn A. PMID: 35406487; PMCID: PMC8996937.
    View in: PubMed Mentions: 8
  18. Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. Int J Mol Sci. 2022 Feb 25; 23(5). Morrison G, Buckley J, Ostrow D, Varghese B, Cen SY, Werbin J, Ericson N, Cunha A, Lu YT, George T, Smith J, Quinn D, Duddalwar V, Triche T, Goldkorn A. PMID: 35269713; PMCID: PMC8910093.
    View in: PubMed Mentions: 9 Fields:
    Translation:HumansCells
  19. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441. Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM. PMID: 33568346; PMCID: PMC8219246.
    View in: PubMed Mentions: 43 Fields:
    Translation:HumansCTClinical Trials
  20. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021 04 01; 27(7):1967-1973. Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. PMID: 33500355; PMCID: PMC8026618.
    View in: PubMed Mentions: 22 Fields:
    Translation:HumansCellsCTClinical Trials
  21. Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. Int J Cancer. 2020 05 15; 146(10):2845-2854. Morrison GJ, Cunha AT, Jojo N, Xu Y, Xu Y, Kwok E, Robinson P, Dorff T, Quinn D, Carpten J, Manojlovic Z, Goldkorn A. PMID: 32037533; PMCID: PMC7451020.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCells
  22. Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype. Int J Cancer. 2020 06 01; 146(11):3065-3076. Xu T, Li HT, Wei J, Li M, Hsieh TC, Lu YT, Lakshminarasimhan R, Xu R, Hodara E, Morrison G, Gujar H, Rhie SK, Siegmund K, Liang G, Goldkorn A. PMID: 32017074; PMCID: PMC7448727.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  23. Current status of liquid biopsies for the detection and management of prostate cancer. Cancer Manag Res. 2019; 11:5271-5291. Lu YT, Delijani K, Mecum A, Goldkorn A. PMID: 31239778; PMCID: PMC6559244.
    View in: PubMed Mentions: 40
  24. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432; PMCID: PMC7446934.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCellsCTClinical Trials
  25. Multiparametric liquid biopsy analysis in metastatic prostate cancer. JCI Insight. 2019 03 07; 4(5). Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, Xu Y, Dempsey PW, Pagano PC, Bischoff F, Khurana A, Koo S, Ting M, Cotter PD, Moore MW, Gunn S, Usher J, Rabizadeh S, Danenberg P, Danenberg K, Carpten J, Dorff T, Quinn D, Goldkorn A. PMID: 30702443; PMCID: PMC6483502.
    View in: PubMed Mentions: 30 Fields:
    Translation:HumansCells
  26. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. PMID: 30128950; PMCID: PMC6342617.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCTClinical Trials
  27. Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. Urol Oncol. 2019 05; 37(5):313-317. Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ. PMID: 30115512; PMCID: PMC6886001.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  28. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treat Res Commun. 2018; 16:18-23. Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI. PMID: 31298998; PMCID: PMC6628720.
    View in: PubMed Mentions: 4 Fields:
  29. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. Curr Oncol Rep. 2018 03 23; 20(4):35. Morrison GJ, Goldkorn A. PMID: 29572775; PMCID: PMC7446728.
    View in: PubMed Mentions: 23 Fields:
    Translation:HumansCells
  30. Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond. Cancer Treat Res. 2018; 175:87-104. Zainfeld D, Goldkorn A. PMID: 30168118; PMCID: PMC7450827.
    View in: PubMed Mentions: 14 Fields:
    Translation:HumansCells
  31. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017 Nov 01; 28(11):2658-2669. Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. PMID: 29045523.
    View in: PubMed Mentions: 38 Fields:
    Translation:Humans
  32. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 12; 15(6):635-641. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. PMID: 28579151; PMCID: PMC5734863.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  33. Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine. Front Oncol. 2017; 7:6. Hugen CM, Zainfeld DE, Goldkorn A. PMID: 28191452; PMCID: PMC5269447.
    View in: PubMed Mentions: 5
  34. Telomere and Telomerase Therapeutics in Cancer. Genes (Basel). 2016 May 26; 7(6). Xu Y, Goldkorn A. PMID: 27240403; PMCID: PMC4929421.
    View in: PubMed Mentions: 54 Fields:
  35. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. PMID: 26771938; PMCID: PMC7455032.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  36. Editorial Comment. J Urol. 2015 Sep; 194(3):798. Goldkorn A. PMID: 26072034.
    View in: PubMed Mentions: Fields:
    Translation:HumansCells
  37. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015 Jul; 107(7). Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M. PMID: 25972604; PMCID: PMC4651042.
    View in: PubMed Mentions: 215 Fields:
    Translation:HumansCells
  38. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. PMID: 25219358; PMCID: PMC4323674.
    View in: PubMed Mentions: 26 Fields:
    Translation:HumansCellsCTClinical Trials
  39. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther. 2014 Nov; 14(11):1257-60. Hu B, Goldkorn A. PMID: 25199875.
    View in: PubMed Mentions: Fields:
    Translation:HumansCells
  40. New prostate cancer drugs: extending and improving life. Lancet Oncol. 2014 Sep; 15(10):1052-4. Agarwal N, Dorff T, Goldkorn A. PMID: 25104108.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  41. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. PMID: 24616308; PMCID: PMC3970171.
    View in: PubMed Mentions: 154 Fields:
    Translation:HumansCellsCTClinical Trials
  42. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. PMID: 24565955; PMCID: PMC3982883.
    View in: PubMed Mentions: 33 Fields:
    Translation:HumansCTClinical Trials
  43. Circulating tumor cells in prostate cancer. Cancers (Basel). 2013 Dec 04; 5(4):1676-90. Hu B, Rochefort H, Goldkorn A. PMID: 24305656; PMCID: PMC3875960.
    View in: PubMed Mentions: 21
  44. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. PMID: 24099865.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCTClinical Trials
  45. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer. 2014 Jan 01; 134(1):43-54. He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. PMID: 23784558.
    View in: PubMed Mentions: 38 Fields:
    Translation:HumansCells
  46. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. PMID: 23871417; PMCID: PMC4277263.
    View in: PubMed Mentions: 83 Fields:
    Translation:HumansCTClinical Trials
  47. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol. 2013 Jul; 24(7):1717-1720. Goldkorn A, Aparicio AM, Quinn DI. PMID: 23798673.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  48. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther. 2012 Nov; 11(11):2462-72. Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC. PMID: 22933703.
    View in: PubMed Mentions: 46 Fields:
    Translation:HumansAnimalsCells
  49. Telomerase targeted therapy in cancer and cancer stem cells. Clin Adv Hematol Oncol. 2011 Jun; 9(6):442-55. Xu Y, He K, Goldkorn A. PMID: 21841744.
    View in: PubMed Mentions: 12 Fields:
    Translation:HumansAnimalsCells
  50. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther. 2011 Jun; 10(6):938-48. He K, Xu T, Goldkorn A. PMID: 21518726; PMCID: PMC3112267.
    View in: PubMed Mentions: 31 Fields:
    Translation:HumansAnimalsCells
  51. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate. 2011 Sep 15; 71(13):1390-400. Xu T, He K, Wang L, Goldkorn A. PMID: 21321978; PMCID: PMC3123672.
    View in: PubMed Mentions: 11 Fields:
    Translation:HumansAnimalsCells
  52. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res. 2010 Aug 15; 70(16):6420-6. Xu T, Lu B, Tai YC, Goldkorn A. PMID: 20663903; PMCID: PMC2922429.
    View in: PubMed Mentions: 57 Fields:
    Translation:HumansCells
  53. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Ther. 2010 Feb; 9(2):438-49. Xu T, Xu Y, Liao CP, Lau R, Goldkorn A. PMID: 20124445; PMCID: PMC2820598.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansAnimalsCells
  54. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. Dorff TB, Goldkorn A, Quinn DI. PMID: 21789121; PMCID: PMC3125999.
    View in: PubMed Mentions: 11
  55. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 2006 Jun 01; 66(11):5763-71. Goldkorn A, Blackburn EH. PMID: 16740715.
    View in: PubMed Mentions: 18 Fields:
    Translation:HumansCells
  56. Cortical variability and asymmetry in normal aging and Alzheimer's disease. Cereb Cortex. 1998 Sep; 8(6):492-509. Thompson PM, Moussai J, Zohoori S, Goldkorn A, Khan AA, Mega MS, Small GW, Cummings JL, Toga AW. PMID: 9758213.
    View in: PubMed Mentions: 79 Fields:
    Translation:Humans
  57. Sulcal variability in the Alzheimer's brain: correlations with cognition. Neurology. 1998 Jan; 50(1):145-51. Mega MS, Thompson PM, Cummings JL, Back CL, Xu ML, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. PMID: 9443471.
    View in: PubMed Mentions: 9 Fields:
    Translation:Humans

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs